Religare Enterprises Ltd
Religare Enterprise Ltd, incorporated in 1984, is a diversified financial services company with presence all over India, operating through its subsidiaries. The Co. provides loans to SMEs, Affordable Housing Finance, Health Insurance and Retail Broking. REL’s subsidiaries service over 11 lakh clients from over 1,275 locations having presence in more than 400 cities.[1][2]
- Market Cap ₹ 7,650 Cr.
- Current Price ₹ 222
- High / Low ₹ 285 / 197
- Stock P/E
- Book Value ₹ 74.1
- Dividend Yield 0.00 %
- ROCE -1.27 %
- ROE -1.48 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Company is almost debt free.
Cons
- Stock is trading at 3.04 times its book value
- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of -41.3% over past five years.
- Promoter holding is low: 30.6%
- Company has a low return on equity of -2.09% over last 3 years.
- Company's cost of borrowing seems high
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 114 | 497 | 35 | 57 | 33 | 21 | 114 | 28 | 32 | 23 | 40 | 8 | 6 | |
| 11 | 8 | 30 | 346 | 136 | 194 | 49 | 52 | 56 | 66 | 62 | 43 | 50 | |
| Operating Profit | 103 | 490 | 5 | -290 | -102 | -174 | 64 | -25 | -24 | -43 | -22 | -35 | -43 |
| OPM % | 91% | 98% | 13% | -508% | -307% | -845% | 57% | -88% | -76% | -185% | -56% | -448% | -669% |
| 0 | -279 | -7 | 15 | 2 | -130 | 5 | 2 | 24 | 2 | 2 | 8 | 11 | |
| Interest | 194 | 110 | 156 | 57 | 45 | 6 | 4 | 2 | 12 | 25 | 15 | 4 | 3 |
| Depreciation | 3 | 2 | 0 | 2 | 1 | 1 | 1 | 2 | 3 | 6 | 5 | 2 | 2 |
| Profit before tax | -93 | 99 | -158 | -333 | -146 | -310 | 64 | -27 | -15 | -72 | -41 | -34 | -37 |
| Tax % | 11% | 16% | 1% | -2% | 0% | 0% | 1% | -3% | -0% | -9% | -9% | -0% | |
| -104 | 84 | -159 | -326 | -146 | -310 | 64 | -26 | -15 | -65 | -38 | -34 | -37 | |
| EPS in Rs | -5.80 | 4.70 | -8.93 | -18.28 | -6.73 | -12.02 | 2.47 | -0.82 | -0.47 | -1.98 | -1.14 | -1.02 | -1.11 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | -34% |
| 5 Years: | -41% |
| 3 Years: | -37% |
| TTM: | 74% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -34% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | -2% |
| 5 Years: | 5% |
| 3 Years: | -2% |
| 1 Year: | -13% |
| Return on Equity | |
|---|---|
| 10 Years: | -5% |
| 5 Years: | -2% |
| 3 Years: | -2% |
| Last Year: | -1% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 178 | 178 | 178 | 178 | 217 | 258 | 259 | 319 | 324 | 330 | 331 | 333 |
| Reserves | 2,253 | 2,337 | 1,679 | 1,330 | 1,442 | 1,252 | 1,320 | 1,819 | 1,823 | 1,793 | 1,759 | 2,134 |
| 750 | 844 | 1,302 | 548 | 381 | 333 | 339 | 93 | 219 | 140 | 44 | 6 | |
| 2,578 | 1,248 | 892 | 186 | 172 | 383 | 243 | 255 | 42 | 141 | 109 | 100 | |
| Total Liabilities | 5,759 | 4,607 | 4,051 | 2,243 | 2,212 | 2,227 | 2,161 | 2,486 | 2,407 | 2,405 | 2,242 | 2,573 |
| 2 | 1 | 0 | 2 | 1 | 2 | 4 | 15 | 16 | 20 | 11 | 6 | |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 5,319 | 4,338 | 3,940 | 2,121 | 2,112 | 2,066 | 1,960 | 2,284 | 2,265 | 2,261 | 2,206 | 2,485 |
| 438 | 268 | 111 | 119 | 98 | 158 | 198 | 187 | 126 | 124 | 26 | 81 | |
| Total Assets | 5,759 | 4,607 | 4,051 | 2,243 | 2,212 | 2,227 | 2,161 | 2,486 | 2,407 | 2,405 | 2,242 | 2,573 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 479 | -93 | 93 | -262 | -26 | -10 | -1 | -19 | -40 | -72 | 79 | -102 | |
| 0 | 0 | -51 | 493 | -86 | -53 | -63 | -311 | 61 | 9 | 54 | -277 | |
| -552 | 94 | -41 | -233 | 115 | 60 | 74 | 320 | 11 | 36 | -131 | 373 | |
| Net Cash Flow | -73 | 1 | 1 | -1 | 3 | -3 | 10 | -10 | 33 | -27 | 2 | -6 |
| Free Cash Flow | 479 | -93 | 93 | -266 | -25 | -11 | -1 | -23 | -40 | -74 | 78 | -102 |
| CFO/OP | 467% | -18% | 2,037% | 91% | 25% | 6% | -2% | 78% | 165% | 167% | -351% | 289% |
Ratios
Standalone / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Inventory Days | ||||||||||||
| Days Payable | ||||||||||||
| Cash Conversion Cycle | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Working Capital Days | -2,542 | -220 | -9,728 | -766 | -866 | -5,391 | -607 | -2,632 | 199 | -1,329 | -843 | -3,782 |
| ROCE % | 3% | 4% | 0% | -11% | -5% | -7% | 4% | -1% | -0% | -2% | -1% | -1% |
Insights
In beta| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Care Health Insurance Gross Written Premium (GWP) Rs. Crore |
|
||||||||||
| Care Health Insurance Investment Book (AUM) Rs. Crore |
|||||||||||
| Care Health Insurance Market Share (SAHI segment) % |
|||||||||||
| Care Health Insurance Number of Branches count |
|||||||||||
| Religare Broking Active Clients thousands |
|||||||||||
| RHDFCL Assets Under Management (AUM) Rs. Crore |
|||||||||||
Extracted by Screener AI
Documents
Announcements
- Announcement under Regulation 30 (LODR)-Newspaper Publication
- Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
-
Announcement under Regulation 30 (LODR)-Allotment
- 22,000 equity shares allotted on ESOP exercise; paid-up capital rose to Rs 3,44,75,57,420 on Oct 7, 2026.
-
Update About Appointment In Subsidiary
- Religare Finvest appoints Gaurav Sharma as CTO effective October 6, 2026.
- Closure of Trading Window
Annual reports
-
Annual Report 2026
from bse
-
Annual Report 2025
from bse
-
Annual Report 2024
from bse
-
Annual Report 2023
from bse
-
Annual Report 2022
from bse
-
Annual Report 2021
from bse
-
Annual Report 2020
from bse
-
Annual Report 2019
from bse
-
Annual Report 2018
from bse
-
Annual Report 2017
from bse
-
Annual Report 2016
from bse
-
Annual Report 2015
from bse
-
Annual Report 2014
from bse
-
Annual Report 2013
from nse
-
Annual Report 2013
from bse
Concalls
-
Aug 2026Transcript PPT REC
-
May 2026Transcript PPT REC
-
Feb 2026Transcript PPT REC
-
Nov 2025Transcript PPT
-
Aug 2023PPT
-
May 2016PPT
-
Feb 2016PPT
-
Nov 2015PPT
-
Aug 2015PPT
Business Overview:[1][2][3]
Religare Enterprises Limited (REL) is a
RBI-registered Core Investment Company
operating through subsidiaries across health insurance, broking, e-governance, secured MSME lending, and affordable housing finance.